HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Adjusts Price Target To $30 (reverse stock split 1:20)
Company Profile
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.